EMA/434296/2021

European Medicines Agency decision

P/0329/2021

of 11 August 2021

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP01-13-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0329/2021

of 11 August 2021

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP01-13-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0169/2014 issued on 7 July 2014, decision P/0122/2015 issued on 5 June 2015, decision P/0072/2016 issued on 18 March 2016, decision P/0219/2016 issued on 12 August 2016, decision P/0069/2017 issued on 3 April 2017, decision P/0158/2018 issued on 15 June 2018, and decision P/0374/2019 of 22 November 2019,

Having regard to the application submitted by Regeneron Pharmaceuticals, Inc on 1 March 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 June 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dupilumab (Dupixent), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Road, 10591 – Tarrytown, USA.

EMA/PDCO/215300/2021
Amsterdam, 25 June 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001501-PIP01-13-M07

Scope of the application

Dupilumab

Invented name:

Dupixent

Condition(s):

Treatment of atopic dermatitis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Regeneron Pharmaceuticals, Inc

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Regeneron Pharmaceuticals, Inc submitted to the European Medicines Agency on 1 March 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0169/2014 issued on 7 July 2014, decision P/0122/2015 issued on 5 June 2015, decision P/0072/2016 issued on 18 March 2016, decision P/0219/2016 issued on 12 August 2016,

decision P/0069/2017 issued on 3 April 2017, decision P/0158/2018 issued on 15 June 2018, and decision P/0374/2019 of 22 November 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 April 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of atopic dermatitis

The waiver applies to:

- the paediatric population from birth to less than 6 months;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition

Treatment of atopic dermatitis

2.1.1. Indication(s) targeted by the PIP

Treatment of atopic dermatitis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	0	**Study 1** Study removed during PIP modification procedure EMEA-001501-PIP01-13-M07.
Non-clinical studies	0	Not applicable
Clinical studies	5	**Study 2** Open-label study to characterize the safety and PK of a single administration of dupilumab in paediatric patients from 6 to less than 18 years of age

		Study 3 Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in paediatric patients from 12 to less than 18 years of age with moderate to severe atopic dermatitis **Study 4** Study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in patients from 6 months to less than 6 years of age with severe atopic dermatitis (AD) **Study 5** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in paediatric patients (from 6 years to less than 12 years of age) with severe atopic dermatitis **Study 6** Randomized, double-blind, placebo controlled study to assess the efficacy of dupilumab in paediatric patients (from 6 months to less than 6 years of age) with severe atopic dermatitis
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of atopic dermatitis

Authorised indication(s):

- Adults and adolescents

  Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

- Children 6 to 11 years of age

  Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

2. Treatment of asthma

Authorised indication(s):

- Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO, who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment.

3. Treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP)

Authorised indication(s):

- Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use